Proposed MU Rules Draw Strong Reaction
American Medical Association (AMA) and 98 state and specialty medical societies:
The AMA sides with the AHA in terms of meeting a requirement for online access to patient health information. The 10% requirement "unfairly predicates the physician's success for meeting the measure on patient compliance and should be eliminated."
For Stage 2, CMS proposes that 50% of all unique patients seen by the physician be provided online access to their health information within four business days after the information is available to the physician. The AMA would like the threshold requirement to be 20% not 50%. AMA contends that the four-day timeframe is "inconsistent with the HIPAA."
It notes that for Stage 2, CMS proposes that the reporting period be the entire calendar year. "The sheer volume of patient information that has to be made available within four business days for the entire calendar year would be extraordinary for most practices and their staff to manage."
The AMA opposes back-dating of the MU penalty program, or for that matter, any other quality or health IT penalty program, including e-prescribing and PQRS. "If Congress intended that these penalty programs be back-dated, the legislation would have stated so. CMS is essentially pushing up deadlines for participation by a full year or more due largely to its own data processing limitations." The AMA asks CMS to allow physicians to successfully meet Stage 2 MU measures for 90 consecutive days during the first six months of 2015 to avoid the 2015 penalty. It says the process should be extended to 2016 and 2017.
- CNO Leads $1M Charge for New Scrubs, Uniforms
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Transforming Cancer Care
- Acute Kidney Injury Gets New Focus
- Interventional Radiology No Longer a Sub-Specialty
- Sharp HealthCare Leaves Pioneer ACO Program
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- mHealth Tackles Readmissions
- MA an Insurance Proving Ground for Providers
- Proton Beam Therapy Poised for Growth in US